All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
• Entremed Inc., of Rockville, Md., said it started a Phase II study, titled “Phase II Study of Oral ENDM-2076 Administered to Patients with Ovarian Clear Cell Carcinomas.”
